Clinical trials: Hospital-acquired Pneumonia
Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia
Real-World Study of Ceftazidime Avibactam in China
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
- Conditions
- Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections
- Trial name
- REACT (NCT05487586)
- Testing
- ceftazidime avibactam group
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Pfizer
Pneumonia, Bacterial, Extracorporeal Membrane Oxygenation
" Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation "
Pneumonia are the most frequent infectious complication in patients on Extracorporeal Membrane Oxygenation Veno-arterial (ECMO-VA), with a treatment failure rate of around 40%, even though antibiotic therapy is tailored to the…
- Trial name
- NAVAP-ECMO (NCT06602557)
- Testing
- Amikacin, Standard of care
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumonia, Ventilator-Associated
Comparison Between Two Methods of Oral Care on the Incidence of VAP
Patients on ventilator are in high risk to develop ventilator associated pneumonia (VAP). This acquired infection significantly increases morbidity and mortality of these patients.
- Trial name
- NCT00521677
- Testing
- Sage oral care, Traditional oral care
- Where
- Israel
- Volunteers
- 108 people
- Sponsor
- HaEmek Medical Center, Israel
Hospital Acquired Pneumonia
Predictors and Outcomes of Ventilated Hospital-acquired Pneumonia
Hospital-acquired pneumonia (HAP) is defined as an infection of the pulmonary parenchyma that develops in patients admitted to hospital for more than 48 hours and that was not incubating at the time of admission.
- Trial name
- NCT07667582
- Testing
- mechanical ventilation (MV)
- Where
- Egypt
- Volunteers
- 151 people
- Sponsor
- Assiut University
Bacterial Pneumonia
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
- Trial name
- NCT00080496
- Testing
- Tigecycline, Imipenem, Cilastatin
- Where
- 29 sites in United States
- Volunteers
- 430 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hospital-Acquired Pneumonia
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient…
- Trial name
- NCT04774094
- Testing
- Zavicefta, Ceftazidime-Avibactam
- Where
- 56 sites in China
- Volunteers
- 235 people
- Sponsor
- Pfizer
Pneumonia
A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.
- Trial name
- NCT00034736
- Testing
- Levofloxacin
- Volunteers
- 691 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Community-Acquired Pneumonia, Pediatric Pneumonia
Clinical Predictors of Severity in Pediatric Community-Acquired Pneumonia at Assiut University Children's Hospital
This study aims to identify the clinical factors that predict the severity of community-acquired pneumonia (CAP) in pediatric patients.
- Conditions
- Community-Acquired Pneumonia, Pediatric Pneumonia, Lower Respiratory Tract Infection
- Trial name
- CAP-Severity (NCT07279675)
- Testing
- Assessment of Pneumonia Severity
- Volunteers
- 67 people
- Sponsor
- Assiut University
Pneumonia
A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)
This study is part of a research program too see if amikacin delivered as an aerosol directly to the lungs in combination with IV antibiotic therapy can help intubated patients with gram-negative pneumonia get better faster than…
- Trial name
- NCT01004445
- Testing
- Amikacin (BAY41-6551)
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Bayer
Nosocomial Pneumonia
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).
- Trial name
- NCT04223752
- Testing
- Ceftolozane/Tazobactam
- Where
- 24 sites in United States, Chile and 7 more
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC